ZYLÖ IN THE NEWS
Zylö announces the creation and spinout of
Finch Pharma Inc.
Focus is on diverse applications of the innovative SNO-pod™ nitric-oxide delivery platform
GREENVILLE, SC, August 30, 2025: Zylö recently effected a spinout of Finch Pharma Inc., whose mission is to unlock the value of the patented SNO-pod™ delivery platform, which features sustained release of nitric oxide (or NO), an important molecule in the human body with wide-ranging mechanisms of action.
NO, a gas in its natural state, was voted Molecule of the Year in 1995 and is often referred to as the “miracle molecule.” It led to the Nobel Prize for Medicine in 1998 for the scientists that discovered its role. It is a potent therapeutic agent, as it is vasodilatory (increases blood flow), anti-inflammatory, anti-microbial, and biofilm-disrupting; it is also a powerful anti-oxidant. With age, the ability to produce NO diminishes, leading to various complications, including wound-healing issues, cardiovascular disease, and erectile dysfunction.
The challenge with supplying NO exogenously is its half-life, which is less than a second. With the sustained-release mechanism of SNO-pods, however, this fleeting gas gets sustainably released back into the body for 24+ hours with a single topical application.
Zylö's ED Product Concept Wins "Best Abstract" Award
The Sexual Medicine Society of North America presented the 'Best Abstract for Basic Science' award to the abstract that describes the work and findings related to Zylö's SNO-pod technology (nitric-oxide-releasing topical, called SNO-pods) for the treatment of ED.
$1.7M NIH Grant Awarded
This award is to advance Zylö's program to treat Erectile Dysfunction patients that do not respond to PDE5 inhibitors such as Viagra....an addressable market exceeding $2B/year in the U.S. alone. Funds to be used for scale-up (with ISO-9001 and cGMP quality systems) and for IND-enabling studies so that Phase 1 human trials can begin.
Endocannabinoid-Loaded Z-pods® Show Efficacy Against Lupus Lesions
Dr. Adam Friedman directed session F003 ‘Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics’ at the American Academy of Dermatology on February 16, 2018. During the session, he presented the lecture “The Potential of Cannabinoids for the Treatment of Inflammatory and Neoplastic Diseases of the Skin” which included exciting new data demonstrating that endocannabinoid-loaded Z-pods significantly reduce the size and severity of lesions in a cutaneous lupus animal model.
"NITRIC OXIDE-RELEASING MICROPARTICLES AS A POTENT ANTIMICROBIAL THERAPEUTIC AGAINST CHRONIC RHINOSINUSITIS BACTERIAL ISOLATES"
A collaborative effort led by Waleed Abuzeid MD, Assistant Professor at Montefiore Hospital, and Joel Friedman MD PhD, Professor at Einstein College of Medicine, yielded early success in a promising new approach for chronic rhino sinusitis using Zylö’s SNO-pods™.